In the t‐CEA + group, the 5‐year survival rates were 100% (n = 27), 100% (n = 35), and 80.9% (n = 89) for patients with stage I, II, and III CRC, respectively; in the t‐CEA ++ group, 100% (n = 27), 83.6% (n = 53), and 58.2% (n = 122), respectively; and in the t‐CEA +++ group, 75% (n = 13), 51.8% (n = 50), and 22.4% (n = 101), respectively. This evidence concerns the gene CEACAM5 and colorectal carcinoma.